In recent years, Cinfa Biotech used its resources to advance B12019, a biosimilar copy of Amgen’s chemotherapy-induced neutropenia drug Neulasta, through clinical trials. B12019 and Neulasta are ...

Neulasta (pegfilgrastim) is a prescription drug used to help prevent infection from certain types of chemotherapy and to treat radiation sickness. Neulasta can interact with certain other ...

Amgen’s Neulasta is set to face its first competition in the US after the FDA approved Mylan’s biosimilar version of the blockbuster cancer infection biologic. Neulasta brought in $4.5 billion ...

PISCATAWAY, N.J.--(BUSINESS WIRE)--Kashiv BioSciences, LLC (“Kashiv” or the “Company”) today announced that Health Canada has granted marketing authorization for its Pegfilgrastim ...

The marketing authorization follows a rigorous regulatory review by Health Canada, ensuring that Kashiv’s Pegfilgrastim Injection meets the stringent quality, safety, and efficacy standards ...

As a result Neulasta was still Amgen’s second biggest selling drug last year, with the US accounting for nearly $3.9 billion in sales, with only $609 million coming from the rest of the world.

PISCATAWAY, N.J. — Kashiv BioSciences, LLC (“Kashiv” or the “Company”) today announced that Health Canada has granted marketing authorization for its Pegfilgrastim Injection, enabling its commercial ...

Kashiv BioSciences, LLC (“Kashiv” or the “Company”) today announced that Health Canada has granted marketing authorization for its Pegfilgrastim Injection, enabling its commercial launch ...